Novel Therapeutic Targets and Approaches for the Treatment for Alzheimer's Disease

Dear Colleagues,

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia worldwide, and is characterized by significant memory decline and cognitive dysfunction attributed to classical neuropathological hallmarks, such as amyloid-beta (Aβ) plaques and the formation of neurofibril tangles in the brain. However, emerging evidence suggests that neuroinflammation, mediated by activated neuroglial cells, neutrophils, and macrophages, also plays an essential role in the pathogenesis of AD. Currently, with the exception of treatment that offers symptomatic relief by blocking N-methyl-D-aspartate (NMDA) receptors or cholinesterase activity, no cure or disease-modifying treatment is available for AD.  The main goal of this Special Issue is to highlight the latest breakthroughs and advancements in the development of target treatments and personalized therapeutic approaches for Alzheimer's disease. Particular attention will be given to novel therapeutic targets for pharmacological intervention, new biologically active compounds, and therapeutic strategies based on recent achievements in identifying genetic and epigenetic determinants of the onset and progression of Alzheimer's disease.  We invite authors to submit research articles, comprehensive reviews, or short communications addressing recent developments in identifying and validating novel therapeutic targets for Alzheimer’s disease, whether by exploring emerging molecular pathways or promising drug candidates, or developing innovative treatment modalities. 

Dr. Marta Rusek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• neurodegenerative diseases
• Alzheimer's disease
• molecular mechanism
• drug delivery
• drug development
• potential therapeutic
• advanced therapies
• disease-modifying therapy
• personalized therapy
• clinical trials